Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 1,601–1,700 of 15,747
Mazzola, A., Todesco, È., Drouin, S., Hazan, F., Marot, S., Thabut, D., Varnous, S., Soulié, C., Barrou, B., Marcelin, A., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab580 · Cited by 76
Zhang, Z., Shen, Q., & Chang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843928 · Cited by 76
“In the phase III CT, 43,448 healthy individuals were arbitrarily selected to receive injections: 21,720 with BNT162b2 and 21,728 with placebo (111).”
MethodWang, Z., Cui, K., Costabel, U., & Zhang, X. (2022) · Exploration · doi:10.1002/exp.20210082 · Cited by 67
Francica, J. R., Flynn, B. J., Foulds, K. E., Noe, A. T., Werner, A. P., Moore, I. N., Gagne, M., Johnston, T. S., Tucker, C., Davis, R. L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi4547 · Cited by 66
Chen, M. Z., Yuen, D., McLeod, V. M., Yong, K. W., Smyth, C. H., Herling, B. R., Payne, T. J., Fabb, S. A., Belousoff, M. J., Algarni, A., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01954-9 · Cited by 114
“The successful deployment of two mRNA/lipid nano-particle (LNP) vaccines to combat the COVID-19 pandemic has demonstrated the potential of LNPs to effectively deliver large synthetic mRNA payloads in vivo 2,3 .”
Tian, F., Yang, R., & Chen, Z. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27940 · Cited by 73
“They are lipid nanoparticle‐formulated, nucleoside‐modified RNA vaccines that encode a full‐length SARS‐CoV‐2 spike protein.(33,34) Essentially, a piece of the sequenced genetic code of the virus is encoded within a fat molecule.”
BackgroundFavresse, J., Bayart, J., Mullier, F., Dogné, J.-M., Closset, M., & Douxfils, J. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.004 · Cited by 72
Moore, J. X., Gilbert, K. L., Lively, K. L., Laurent, C., Chawla, R., Li, C., Johnson, R., Petcu, R., Mehra, M., Spooner, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9080879 · Cited by 71
Artificial intelligence in accelerating vaccine development - current and future perspectives
Kaushik, R. K., Kant, R., & Christodoulides, M. (2023) · Frontiers in Bacteriology · doi:10.3389/fbrio.2023.1258159 · Cited by 74
Targeting aging and age-related diseases with vaccines
Wu, R., Sun, F., Zhang, W., Ren, J., & Liu, G.-H. (2024) · Nature Aging · doi:10.1038/s43587-024-00597-0 · Cited by 66
“These nontraditional vaccines include adenovirus, retrovirus, nucleic acid, cell-based vaccines and so on 24–27 (Fig.”
Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients
Malinis, M. F., Cohen, E., & Azar, M. M. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16713 · Cited by 65
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
Coughlan, L., Kremer, E. J., & Shayakhmetov, D. M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.034 · Cited by 71
Schiaffino, S., Pinker, K., Magni, V., Cozzi, A., Athanasiou, A., Baltzer, P., Herrero, J. C., Clauser, P., Fallenberg, E. M., Forrai, G., et al. (2021) · Insights into Imaging · doi:10.1186/s13244-021-01062-x · Cited by 67
“Conversely, in the phase III trial of the Pfizer–BioNTech vaccine [21], lymphadenopathy was reported in 0.”
BackgroundWirawan, G. B. S., Mahardani, P. N. T. Y., Cahyani, M. R. K., Laksmi, N. L. P. S. P., & Januraga, P. P. (2021) · Personality and Individual Differences · doi:10.1016/j.paid.2021.110995 · Cited by 84
Leidi, A., Koegler, F., Dumont, R., Dubos, R., Zaballa, M.-E., Piumatti, G., Coen, M., Berner, A., Farhoumand, P. D., Vetter, P., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab495 · Cited by 66
Gilbert, J., Sebastiani, F., Arteta, M. Y., Terry, A. E., Fornell, A., Russell, R. A., Mahmoudi, N., & Nylander, T. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.12.165 · Cited by 78
A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant
Chang, Y., Yang, C., Chen, Y., Yang, C., Chou, Y., Chou, H., Chang, T.-Y., Chao, T., Hsu, S., Ieong, S., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115298 · Cited by 72
“The effectiveness of ChAdOx1 nCoV-19, BNT162b2, and mRNA-1273 vaccine reached 70.4, 95, and 94.1%, respectively (Baden et al, 2021; Knoll & Wonodi, 2021; Wang, 2021).”
BackgroundInfluentialCancer Patients’ Willingness to Take COVID-19 Vaccination: A Nationwide Multicenter Survey in Korea
Chun, J. Y., Kim, S. I., Park, E. Y., Park, S., Koh, S.-J., Cha, Y., Yoo, H. J., Joung, J. Y., Yoon, H. M., Eom, B. W., et al. (2021) · Cancers · doi:10.3390/cancers13153883 · Cited by 70
“Meanwhile, the Korean Ministry of Food and Drug Safety approved Pfizer-BioNTech/BNT162b2 [26] and AstraZeneca/AZD1222 (viral vector) COVID-19 vaccines [29] in February, 2021.”
BackgroundHadi, Y. B., Thakkar, S. J., Shah-Khan, S. M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.014 · Cited by 66
Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern
Farkash, I., Feferman, T., Saban, N. C., Avraham, Y., Morgenstern, D., Mayuni, G., Barth, N., Lustig, Y., Miller, L., Shouval, D. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110114 · Cited by 63
Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease
Ollila, T. A., Lu, S., Masel, R. H., Zayac, A. S., Paiva, K. J., Rogers, R., & Olszewski, A. J. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4381 · Cited by 64
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Oya, Y., Imaizumi, K., & Mitsudomi, T. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107886 · Cited by 65
Havervall, S., Ng, H., Falk, A. J., Greilert‐Norin, N., Månberg, A., Marking, U. W., Laurén, I., Gabrielsson, L., Salomonsson, A., Aguilera, K., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13387 · Cited by 66
Krutikov, M., Palmer, T., Tut, G., Fuller, C., Shrotri, M., Williams, H., Davies, D., Irwin-Singer, A., Robson, J., Hayward, A. C., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00093-3 · Cited by 66
Practical Guide to Honest Causal Forests for Identifying Heterogeneous Treatment Effects
Jawadekar, N., Kezios, K., Odden, M. C., Stingone, J. A., Calonico, S., Rudolph, K., & Zeki Al Hazzouri, A. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad043 · Cited by 66
Covid-19 vaccination: What’s the evidence for extending the dosing interval?
Iacobucci, G., & Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n18 · Cited by 65
Kim, M. S., Jung, S. Y., Ahn, J. G., Park, S.-J., Shoenfeld, Y., Kronbichler, A., Koyanagi, A., Dragioti, E., Tizaoui, K., Hong, S. H., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27424 · Cited by 74
“2,3,6 Although the safety profiles of mRNA vaccines have been evaluated in serial clinical trials, 4,5,7 concerns remain as the safety evaluations in clinical trials were limited to relatively healthy people, excluding vulnerable populations such as children, pregnant women, and individuals with…”
BackgroundAdvanced delivery systems for peptide antibiotics
Cesaro, A., Lin, S., Pardi, N., & de la Fuente‐Núñez, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114733 · Cited by 75
The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
Zitt, E., Davidovic, T., Schimpf, J., Abbassi-Nik, A., Mutschlechner, B., Ulmer, H., Benda, M. A., Sprenger-Mähr, H., Winder, T. L., & Lhotta, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.704773 · Cited by 68
“(5) to evaluate side effects enables the comparison to general population data.”
BackgroundResultInfluentialAn RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis
Larsen, S. E., Erasmus, J. H., Reese, V. A., Pecor, T., Archer, J., Kandahar, A., Hsu, F.-C., Nicholes, K., Reed, S. G., Baldwin, S. L., et al. (2023) · Vaccines · doi:10.3390/vaccines11010130 · Cited by 66
Sourij, C., Tripolt, N. J., Aziz, F., Aberer, F., Forstner, P., Obermayer, A. M., Kojzar, H., Kleinhappl, B., Pferschy, P. N., Mader, J. K., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14643 · Cited by 70
Lee, C.-Y., & Lowen, A. C. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.03.009 · Cited by 76
Kläser, K., Molteni, E., Graham, M. S., Canas, L. S., Österdahl, M. F., Antonelli, M., Chen, L., Deng, J., Murray, B. A. K., Kerfoot, E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-14016-0 · Cited by 66
Controversy surrounding the Sputnik V vaccine
Cazzola, M., Rogliani, P., Mazzeo, F., & Matera, M. G. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106569 · Cited by 71
SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
Tatsi, E., Filippatos, F., & Michos, A. G. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002430 · Cited by 77
“Both vaccines have been found to be highly effective in clinical trials as well as in mass vaccination programmes with tolerable reactogenicity [73].”
BackgroundHuayamares, S. G., Lokugamage, M. P., Rab, R., Da Silva Sanchez, A. J., Kim, H., Radmand, A., Loughrey, D., Lian, L., Hou, Y., Achyut, B. R., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.005 · Cited by 65
Parry, H., Bruton, R. K., Stephens, C., Brown, K. E., Amirthalingam, G., Otter, A. D., Hallis, B., Zuo, J., & Moss, P. A. H. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00246-9 · Cited by 73
Hallett, A. M., Greenberg, R. S., Boyarsky, B. J., Shah, P. D., Ou, M. T., Teles, A. T., Krach, M. R., López, J. I., Werbel, W. A., Avery, R. K., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.026 · Cited by 68
“Age group, y 18-39 7 (24) 9 (31) 13 (45) 40-59 7 (18) 20 (53) 11 (29) ≥60 5 (8) 34 (52) 27 (41) Sex Male 9 (14) 34 (52) 22 (34) Female 9 (13) 30 (45) 28 (42) Race White 17 (14) 59 (49) 44 (37) Non-white 2 (16) 5 (38) 6 (46) Time since transplant, y <3 4 (11) 10 (26) 24 (63) 3-6 6 (15) 19 (46) 16 (39) 7-11 3 (15) 13 (6…”
Huang, J., & Xiao, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081586 · Cited by 79
“For example, Moderna and Pfizer/BioNTech use LNPs to encapsulate mRNA encoding the SARS-CoV-2 antigen, resulting in ~95% protection efficacy [80,81].”
MethodOne year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages
Gónzález‐Candelas, F., Shaw, M., Phan, T. G., Kulkarni‐Kale, U., Paraskevis, D. N., Luciani, F., Kimura, H., & Sironi, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104869 · Cited by 70
Ma, Y., Deng, J., Liu, Q., Du, M., Liu, M., & Liu, J. (2022) · Vaccines · doi:10.3390/vaccines10020246 · Cited by 74
SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines
Rogliani, P., Chetta, A. A., Cazzola, M., & Calzetta, L. (2021) · Vaccines · doi:10.3390/vaccines9030227 · Cited by 64
Landscape and selection of vaccine epitopes in SARS-CoV-2
Smith, C. C., Olsen, K. S., Gentry, K. M., Sambade, M., Beck, W., Garness, J., Entwistle, S., Willis, C., Vensko, S., Woods, A., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00910-1 · Cited by 65
Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G. F., Hussain, T., Tandon, A. A., Kane, C., Avula, S., Duru, C., et al. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.07.044 · Cited by 69
siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses
Sajid, M. I., Moazzam, M., Cho, Y., Kato, S., Xu, A., Way, J. J., Lohan, S., & Tiwari, R. K. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01239 · Cited by 67
Recent developments and applications of smart nanoparticles in biomedicine
Campora, S., & Ghersi, G. (2022) · Nanotechnology Reviews · doi:10.1515/ntrev-2022-0148 · Cited by 84
BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2
Brewer, R. C., Ramadoss, N. S., Lahey, L. J., Jahanbani, S., Robinson, W. H., & Lanz, T. V. (2021) · Nature Immunology · doi:10.1038/s41590-021-01088-9 · Cited by 65
Bochicchio, S., Lamberti, G., & Barba, A. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020198 · Cited by 70
Defending against SARS-CoV-2: The T cell perspective
Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 76
Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study
Garcia-Knight, M., Anglin, K., Tassetto, M., Lu, S., Zhang, A., Goldberg, S. A., Catching, A., Davidson, M. C., Shak, J. R., Romero, M., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010802 · Cited by 63
Duque, J. S. R., Wang, X., Leung, D., Cheng, S. M. S., Cohen, C. A., Mu, X., Hachim, A., Zhang, Y., Chan, S. M., Chaothai, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31485-z · Cited by 65
A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant
Zhang, M., Liang, Y., Yu, D., Du, B., Cheng, W., Li, L., Yu, Z., Luo, S., Zhang, Y., Wang, H., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.68973 · Cited by 72
Souza, P. F. N., Mesquita, F. P., Amaral, J. L., Landim, P. G. C., Lima, K. R. P., Costa, M. B., Farias, I. R., Belém, M. O., Pinto, Y. O., Moreira, H. H. T., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.058 · Cited by 72
“is exposed and externalized to be recognized by the immune system leading to the production of anti-SARS-CoV-2 antibodies [38].”
Ahn, J. Y., Lee, J., Suh, Y. S., Song, Y. G., Choi, Y.-J., Lee, K. H., Seo, S. H., Song, M., Oh, J., Kim, M., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00358-x · Cited by 72
Olayiwola, M. O., Alaje, A. I., Yunus, A. O., & Adedokun, K. A. (2023) · Healthcare Analytics · doi:10.1016/j.health.2023.100179 · Cited by 66
Goldberg, Y., Mandel, M., Woodbridge, Y., Fluss, R., Novikov, I., Yaari, R., Ziv, A., Freedman, L., & Huppert, A. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac060 · Cited by 64
Yau, K., Abe, K. T., Naimark, D. M. J., Oliver, M. J., Perl, J. M., Leis, J. A., Bolotin, S., Tran, V., Mullin, S. I., Shadowitz, E., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.23622 · Cited by 65
Peregrino, E. S., Castañeda‐Casimiro, J., Vázquez-Flores, L., Estrada-Parra, S. A., Baeza, C. W., Serafín‐López, J., & Wong‐Baeza, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116210 · Cited by 70
“They are also approved for their use in two mRNA-LNP vaccines against COVID-19, the BNT162b2 vaccine from Pfizer-BioNTech [214], and the mRNA-1273 vaccine from Moderna [215], both of which are currently in clinical use.”
BackgroundMair, M. J., Berger, J. M., Berghoff, A. S., Starzer, A. M., Ortmayr, G., Puhr, H. C., Steindl, A., Perkmann, T., Haslacher, H., Straßl, R. P., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.5437 · Cited by 71
Irsara, C., Egger, A., Prokop, W., Nairz, M., Loacker, L., Sahanic, S., Pizzini, A., Sonnweber, T., Holzer, B., Mayer, W., et al. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0214 · Cited by 69
Obesity may hamper SARS-CoV-2 vaccine immunogenicity
Pellini, R., Venuti, A., Pimpinelli, F., Abril, E., Blandino, G., Campo, F., Conti, L., de Virgilio, A., Marco, F. D., Domenico, E. D. D., et al. (2021) · medRxiv · doi:10.1101/2021.02.24.21251664 · Cited by 76
Piñana, J. L., López‐Corral, L., Martino, R., Montoro, J., Vázquez, L., Pérez, A., Martin‐Martin, G., Facal‐Malvar, A., Ferrer, E., Pascual, M., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26385 · Cited by 67
“001 17–30 years, n (%) 32 (10) 2 (2) 31–40 years, n (%) 33 (11) 4 (5) 41–50 years, n (%) 54 (17) 10 (12) 51–60 years, n (%) 79 (25) 18 (21) 61–70 years, n (%) 88 (28) 40 (47)”
Post COVID-19 irritable bowel syndrome
Marasco, G., Cremon, C., Barbaro, M. R., Cacciari, G., Falangone, F., Валерьевна, К. А., Bordin, D. S., Drug, V. L., Miftode, E. G., Fusaroli, P., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-328483 · Cited by 79
Obéid, M., Suffiotti, M., Pellaton, C., Bouchaab, H., Cairoli, A., Salvadé, V., Stevenel, C., Hottinger, R., Pythoud, C., Coutechier, L., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0446 · Cited by 68
SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women
Butt, A. A., Chemaitelly, H., Al Khal, A., Coyle, P. V., Saleh, H., Kaleeckal, A. H., Latif, A. N., Bertollini, R., Abou-Samra, A.-B., & Abu-Raddad, L. J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci153662 · Cited by 64
“Early randomized clinical trials using these vaccines reported an efficacy of 94% to 95% in preventing confirmed SARS-CoV-2 infection or symptomatic COVID-19 disease (1, 2).”
BackgroundMyocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines
Vidula, M. K., Ambrose, M., GLASSBERG, H. L., Chokshi, N. P., Chen, T., Ferrari, V. A., & Han, Y. (2021) · Cureus · doi:10.7759/cureus.15576 · Cited by 67
“In the clinical trials assessing the safety of these two-dose vaccines, patients who received the vaccines more commonly experienced higher rates of local injection site reactions, fatigue, and headaches, and there were very few serious adverse events [2,3].”
BackgroundTzioufas, A. G., Bakasis, A., Goules, A. V., Bitzogli, K., Cinoku, I. I., Chatzis, L. G., Argyropoulou, O. D., Venetsanopoulou, A. I., Mavrommati, M., Stergiou, I. Ε., et al. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102743 · Cited by 67
Design and translation of injectable biomaterials
Nguyen, M., Karkanitsa, M. L., & Christman, K. L. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00213-1 · Cited by 81
“For example, lipid nanoparticle-based SARS-CoV-2 mRNA vaccines 145 rely on intramuscular injection.”
Rinott, E., Youngster, I., & Lewis, Y. E. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7009e3 · Cited by 64
Efficacy of COVID-19 vaccines in patients taking immunosuppressants
Shen, C., Risk, M., Schiopu, E., Hayek, S. S., Xie, T., Holevinski, L., Akin, C., Freed, G. L., & Zhao, L. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-222045 · Cited by 71
Saad-Roy, C. M., & Traulsen, A. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2311584120 · Cited by 87
Cottrell, C. A., Hu, X., Lee, J. H., Skog, P. D., Luo, S., Flynn, C. T., McKenney, K. R., Hurtado, J., Kalyuzhniy, O., Liguori, A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn0223 · Cited by 76
“mRNA/LNP vaccine platforms can provide excellent immunogenicity and safety with rapid timelines for entering clinical trials, as illustrated by the SARS-CoV-2 mRNA vaccines (46, 47).”
Hofstraat, S. R. J., Anbergen, T., Zwolsman, R. C., Deckers, J., van Elsas, Y., Trines, M. M., Versteeg, I., Hoorn, D., Ros, G. W. B., Bartelet, B. M., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-024-01847-3 · Cited by 89
“Furthermore, LNP technology was essential for the COVID-19 messenger RNA (mRNA) vaccines 4,5 , and facilitates in vivo gene editing approaches currently undergoing clinical evaluation 6,7 .”
Premenstrual and menstrual changes reported after COVID-19 vaccination: The EVA project
Baena‐García, L., Aparicio, V. A., Molina-López, A., Aranda, P., Cámara-Roca, L., & Hernández, O. O. (2022) · Women s Health · doi:10.1177/17455057221112237 · Cited by 76
“9; (3) not presenting thyroidrelated alterations or treatment; (4) not presenting polycystic ovarian syndrome; (5) not presenting endometriosis; and (6) not presenting severe diseases (e.”
BackgroundA public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike
Claireaux, M. A. F., Caniels, T. G., de Gast, M., Han, J., Guerra, D., Kerster, G., van Schaik, B. D. C., Jongejan, A., Schriek, A. I., Grobben, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32232-0 · Cited by 70
Brief review of the mRNA vaccines COVID-19
Vitiello, A., & Ferrara, F. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00811-0 · Cited by 73
Binici, B., Rattray, Z., Zinger, A., & Perrie, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.010 · Cited by 79
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Ludwig, H., Sonneveld, P., Facon, T. T. F., Miguel, J. F. S., Avet‐Loiseau, H., Mohty, M., Mateos, M.-V., Moreau, P., Cavo, M., Pawlyn, C., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00278-7 · Cited by 70
Sato, K., Mano, T., Niimi, Y., Toda, T., Iwata, A., & Iwatsubo, T. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.08.071 · Cited by 64
Szőke, D., Kovács, G., Kemecsei, É., Bálint, L., Szoták-Ajtay, K., Aradi, P., Styevkóné Dinnyés, A., Mui, B. L., Tam, Y. K., Madden, T. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23546-6 · Cited by 64
Zhou, J., Ye, T., Yang, Y., Li, E., Zhang, K., Wang, Y., Chen, S., Hu, J., Zhang, K., Liu, F., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.028 · Cited by 71
Duarte, L. F., Gálvez, N. M. S., Iturriaga, C., Melo-González, F., Soto, J. A., Schultz, B. M., Urzua, M. D., González, L. A., Vázquez, Y., Ríos, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742914 · Cited by 65
Buckner, C. M., Kardava, L., Merhebi, O. E., Narpala, S., Serebryannyy, L., Lin, B. C., Wang, W., Zhang, X., de Assis, F. L., Kelly, S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.032 · Cited by 69
“The original two-dose BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine elicits antibodies that are highly effective at neutralizing the ancestral virus (Baden et al., 2021; Polack et al., 2020).”
He, W., Musharrafieh, R. G., Song, G., Dueker, K., Tse, L. V., Martinez, D. R., Schäfer, A., Callaghan, S., Yong, P., Beutler, N., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01222-1 · Cited by 59
Supramolecular interaction in the action of drug delivery systems
Geng, W.-C., Jiang, Z.-T., Chen, S., & Guo, D. (2024) · Chemical Science · doi:10.1039/d3sc04585d · Cited by 77
Soheili, M., Khateri, S., Moradpour, F., Mohammadzadeh, P., Zareie, M., Mortazavi, S. M. M., Manifar, S., Kohan, H. G., & Moradi, Y. (2023) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-023-00594-y · Cited by 89
“Pfizer COVID-19 vaccine is a lipid nanoparticle formulation that contains a nucleoside-modified RNA against the S protein of the SARS-CoV-2 virus [21].”
BackgroundAdjobimey, T., Meyer, J., Sollberg, L., Bawolt, M., Berens, C., Kovačević, P., Trudić, A., Parčina, M., & Hoerauf, A. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.917905 · Cited by 75
“Recent data indicate increasing SARS-CoV-2 infection rates and COVID-19 in younger adults due to the occurrence of new virus variants (4, 5).”
BackgroundImmune Escape Mechanism and Vaccine Research Progress of African Swine Fever Virus
Wang, Z., Ai, Q., Huang, S., Ou, Y., Gao, Y., Tong, T., & Fan, H. (2022) · Vaccines · doi:10.3390/vaccines10030344 · Cited by 69
Kissler, S. M., Fauver, J. R., Mack, C. D., Tai, C. G.-L., Breban, M. I., Watkins, A. E., Samant, R. M., Anderson, D. J., Ho, D. D., Grubaugh, N. D., et al. (2021) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 99
A Case of Postural Orthostatic Tachycardia Syndrome Secondary to the Messenger RNA COVID-19 Vaccine
Reddy, S., Reddy, S., & Arora, M. (2021) · Cureus · doi:10.7759/cureus.14837 · Cited by 65
“This spike protein acts as an intracellular antigen, which in turn stimulates the immune system to form neutralizing antibodies that will block viral entry into host cells [18].”
BackgroundTré‐Hardy, M., Cupaiolo, R., Papleux, E., Wilmet, A., Horeanga, A., Antoine-Moussiaux, T., Vecchia, A. D., Beukinga, I., Vekemans, M., & Blairon, L. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.03.025 · Cited by 66
SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19
Ravichandran, S., Tang, J., Grubbs, G., Lee, Y., Pourhashemi, S., Hussaini, L., Lapp, S. A., Jerris, R. C., Singh, V., Chahroudi, A., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01051-8 · Cited by 64
Waning of SARS-CoV-2 booster viral-load reduction effectiveness
Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2022) · Nature Communications · doi:10.1038/s41467-022-28936-y · Cited by 63
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortés, J., Romero, P. J., Mittendorf, E., Disis, M. L., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2153 · Cited by 66
“In particular, BNT162b2 and mRNA-1273 exploit LNPs as vectors for spike protein-encoding mRNAs and are currently being administered in worldwide vaccination campaigns.(23,24) For the first time, such gene-based vaccines have been linked with remarkable safety profiles in the general population, as well as in special s…”
Waning of SARS-CoV-2 booster viral-load reduction effectiveness
(2021) · doi:10.1101/2021.12.27.21268424 · Cited by 63
“To calculate the change in Ct between post-vaccination time bins, we applied the same linear regression model as above, except replacing the length-8 onehot vector of post-vaccination time with a 8-length time-accumulated binary vector indicating [0,0,0,0,0,0,0,0], [1,0,0,0,0,0,0,0], [1,1,0,0,0,0,0,0], [1,1,1,0,0,0,0,…”
MethodThe BNT162b2 mRNA Covid-19 vaccine does not impair sperm parameters
Safrai, M., Herzberg, S., Imbar, T., Reubinoff, B. E., Dior, U. P., & Ben‐Meir, A. (2022) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2022.01.008 · Cited by 64
“This pandemic illness spread to millions of people worldwide, causing severe disease and widespread death, with devastating medical, economic, and social consequences (Polack et al., 2020).”
Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world
Chavda, V. P., Yao, Q., Vora, L. K., Apostolopoulos, V., Patel, C. A., Bezbaruah, R., Patel, A., & Chen, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961198 · Cited by 67
The role of vaccines in the COVID-19 pandemic: what have we learned?
Krammer, F. (2023) · Seminars in Immunopathology · doi:10.1007/s00281-023-00996-2 · Cited by 77
(2021) · doi:10.1101/2021.02.11.430787 · Cited by 942
van den Hoogen, L. L., Smits, G. P., van Hagen, C. C. E., Wong, D., Vos, E. R. A., van Boven, M., de Melker, H. E., van Vliet, J., Kuijer, M., Woudstra, L., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.009 · Cited by 60
“Since late 2020, multiple countries have initiated vaccine rollout against COVID-19 which is caused by severe acute respiratory have been reported shortly after completion of the vaccination regimen [2].”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.